Toronto Transplant Hepatology Fellowship Co Director, Dr. Zita Galvin, will speak at the CST-CTRMS Scientific Meeting on September 27th at 9:40 am in the Liver Concurrent Session (Suite 202)
“Predictors of de novo NAFLD post liver transplantation”
NAFLD is en route to becoming the leading reason for liver transplant in North America, and can recur or present as de novo NAFLD patients transplanted for other indications. This study identifies risk factors for development of de novo NAFLD, and assesses non-invasive fibrosis tools in this context. Diabetes, body mass index and sirolimus-based immunosuppression were the only modifiable factors associated with development of de novo NAFLD. Physicians should maintain a pro-active approach in reducing immunosuppression and counselling on physical activity and diet in patients at risk. Novel fibrosis biomarkers should be sought to screen for fibrosis in de novo NAFLD, given the limited utility of current non-invasive fibrosis tools.